-$0.10 EPS Expected for Incyte Co. (INCY) This Quarter
Analysts predict that Incyte Co. (NASDAQ:INCY) will post earnings of ($0.10) per share for the current quarter, according to Zacks. Sixteen analysts have made estimates for Incyte’s earnings. The highest EPS estimate is $0.30 and the lowest is ($0.33). Incyte reported earnings per share of ($0.96) during the same quarter last year, which suggests a positive year over year growth rate of 89.6%. The company is expected to issue its next quarterly earnings report on Thursday, May 3rd.
On average, analysts expect that Incyte will report full-year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($1.83) to $0.96. For the next financial year, analysts expect that the company will post earnings of $0.41 per share, with EPS estimates ranging from ($1.08) to $2.18. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Incyte.
Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.54. The business had revenue of $444.20 million for the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. The firm’s quarterly revenue was up 36.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.05 EPS.
In related news, insider David W. Gryska sold 6,760 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $98.87, for a total transaction of $668,361.20. Following the transaction, the insider now directly owns 20,752 shares in the company, valued at approximately $2,051,750.24. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Reid M. Huber sold 696 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $98.01, for a total value of $68,214.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,456 shares of company stock worth $1,222,876. 17.70% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Inverness Counsel LLC NY bought a new stake in Incyte during the third quarter valued at about $330,000. LMR Partners LLP acquired a new position in Incyte in the third quarter valued at approximately $394,000. Exane Derivatives acquired a new position in Incyte in the fourth quarter valued at approximately $669,000. Swiss National Bank lifted its stake in Incyte by 3.0% in the third quarter. Swiss National Bank now owns 641,700 shares of the biopharmaceutical company’s stock valued at $74,912,000 after buying an additional 18,700 shares during the period. Finally, Prudential Financial Inc. lifted its stake in Incyte by 0.6% in the third quarter. Prudential Financial Inc. now owns 236,699 shares of the biopharmaceutical company’s stock valued at $27,633,000 after buying an additional 1,490 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.
Shares of Incyte (NASDAQ INCY) traded down $0.80 on Monday, reaching $84.71. The company had a trading volume of 1,366,600 shares, compared to its average volume of 1,808,695. The stock has a market cap of $18,099.38, a PE ratio of -54.69 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.01 and a quick ratio of 3.99. Incyte has a twelve month low of $80.85 and a twelve month high of $153.15.
COPYRIGHT VIOLATION WARNING: “-$0.10 EPS Expected for Incyte Co. (INCY) This Quarter” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/02/22/0-10-eps-expected-for-incyte-co-incy-this-quarter.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.